Please assess the completion status of the following clinical trial:

Trial Title: Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: None
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically proven grade II or III soft tissue sarcoma of one of following high-risk groups:~  * Grade II/III primary tumor with lesion size of at least 5 cm, deep, and extracompartmental (S1)~ * Local recurrence of primary tumor (S2)~ * Inadequate surgical excision of S1 or S2 (S3)~* Disease recurrence after prior surgery allowed~* The following histological types are eligible:~  * Malignant fibrous histiocytoma~ * Liposarcoma (round cell and pleomorphic)~ * Leiomyosarcoma~ * Fibrosarcoma~ * Rhabdomyosarcoma~ * Synovial sarcoma~ * Malignant paraganglioma~ * Neurofibrosarcoma (malignant schwannoma)~ * Extraskeletal Ewing's sarcoma~ * Extraskeletal osteosarcoma~ * Malignant peripheral neuroectodermal tumors~ * Mesenchymal chondrosarcoma~ * Angiosarcoma~ * Miscellaneous sarcoma~ * Unclassified sarcoma~* No distant metastases~PATIENT CHARACTERISTICS:~Age:~* 18 to 70~Performance status:~* WHO 0-2 OR~* Karnofsky 60-100%~Life expectancy:~* Not specified~Hematopoietic:~* WBC at least 3,500/mm\^3~* Platelet count at least 100,000/mm\^3~* No bleeding disorder~Hepatic:~* Bilirubin less than 1.25 times upper limit of normal~* No severe hepatic dysfunction~Renal:~* Creatinine clearance greater than 60 mL/min~* No chronic renal failure~Cardiovascular:~* No documented existing cardiac failure~* No manifest heart failure (New York Heart Association class III or IV)~* Left ventricular ejection fraction no more than 10% below institutional normal~Other:~* No other prior or concurrent malignancy except adequately treated basal cell skin cancer or carcinoma in situ of the cervix~* No other severe disease~* No severe cerebrovascular disease~* No extremely obese patients~* No prior metallic implants relevant to the regional hyperthermia field~* Not pregnant or nursing~PRIOR CONCURRENT THERAPY:~Biologic therapy:~* Not specified~Chemotherapy:~* No prior chemotherapy~Endocrine therapy:~* Not specified~Radiotherapy:~* No prior radiotherapy (except to disease recurrence outside study irradiation field)~Surgery:~* See Disease Characteristics~* No prior mutilative surgery

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).